E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10067585 |
E.1.2 | Term | Type 2 diabetes mellitus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary efficacy objective is to determine, as a superiority assessment, whether treatment with saxagliptin compared with placebo when added to current background therapy will result in a reduction in the composite endpoint of CV death, non-fatal MI or non-fatal ischaemic stroke in patients with T2DM. The primary safety objective is to establish that the upper bound of the 2-sided 95% CI for the estimated risk ratio comparing the incidence of the composite endpoint of CV death, non-fatal MI or non-fatal ischaemic stroke in patients with T2DM observed with saxagliptin to that observed in the placebo group is less than 1.3. |
|
E.2.2 | Secondary objectives of the trial |
The secondary efficacy objective is to determine whether treatment with saxagliptin compared with placebo when added to current background therapy in patients with T2DM will result in a reduction of the composite endpoint of CV death, non-fatal MI, non-fatal ischaemic stroke, hospitalisation for heart failure, hospitalisation for unstable angina pectoris or hospitalization for coronary revascularisation. Safety and tolerability will be evaluated by assessment of overall AEs and AEs of special interest. These will include assessment of the long-term effects of saxagliptin on decrease in lymphocyte counts, decrease in thrombocyte counts, severe infections, hypersensitivity reactions, liver abnormalities, bone fractures, pancreatitis, skin reactions and renal abnormalities. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provision of informed consent prior to any study-specific procedures
2. Age ≥40 years
3. Diagnosed with T2DM based on the current American Diabetes Association guidelines
4. HbA1c ≥6.5% (based on the last measured and documented laboratory measurement in the previous 6 months)
5. High risk for a CV event defined as having either established CV disease and/or multiple risk factors:
Established CV disease: Ischaemic heart disease, and/or Peripheral vascular disease (eg, intermittent claudication), and/or Ischaemic stroke
Multiple Risk Factors Patient must be at least 55 years old (men) and 60 years old (females) and have at least one additional risk factor (treated or non-treated) from the following: Dyslipidemia (based on the last measured and documented laboratory measurement in the previous 6 months and defined as at least 1 of the following): o High level of low-density lipoprotein cholesterol (LDL-C), defined as >130 mg/dL (> 3.36 mmol/L) o Low level of high-density lipoprotein cholesterol (HDL-C), defined as <40 mg/dL (<1.04 mmol/L) for men or <50 mg/dL (<1.30 mmol/L) for women Hypertension, as confirmed at the enrolment visit o BP >140/90 mm/Hg or on a BP-lowering agent with BP >130/80 mm/Hg Currently smoking, as confirmed at the enrolment visit
6. Women of childbearing potential (WOCBP) must take precautions to avoid pregnancy throughout the study and for 4 weeks after intake of the last dose. Men participating in the study should also take precautions not to father a child while participating in the study and for 4 weeks after intake of the last dose. WOCBP must have a negative urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 72 hours prior to the start of study medication. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilisation (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea ≥2 consecutive years). |
|
E.4 | Principal exclusion criteria |
1. Any conditions that, in the opinion of the Investigator, may render the patient unable to complete the study including non-CV disease (eg, active malignancy, cardiomyopathy, cirrhosis, or chronic lung disease) with a likely fatal outcome within 5 years
2. Current or previous (within 6 months) treatment with an incretin-based therapy such as DPP4 inhibitors and or GLP-1 mimetics
3. Acute vascular (cardiac or stroke) event <2 months prior to randomization
4. Initiation of chronic dialysis and/or renal transplant and/or a serum creatinine >6.0 mg/dL
5. Pregnant or breast-feeding patients
6. History of human immunodeficiency virus
7. Patients being treated for severe auto immune diseases such as lupus
8. Any patient currently receiving chronic (>30 consecutive days) treatment with an oral steroid
9. Patients with: Body mass index >50 kg/m2 Last measured HbA1c ≥12% Sustained BP >180/100 mm Hg LDL-C >250 mg/dL (> 6.48 mmol/L) (based on the last measured and documented laboratory measurement in the previous 6 months) Triglycerides >1000 mg/dL (>11.3 mmol/L) (based on the last measured and documented laboratory measurement in the previous 6 months) HDL-C <25 mg/dL (<0.64 mmol/L) (based on the last measured and documented laboratory measurement in the previous 6 months) Known liver function tests >3 times upper limit of normal (ULN), (based on the last measured and documented laboratory measurement in the previous 6 months)
10. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca and BMS or representative staff and/or staff at the study site)
11. Previous randomisation in the present study
12. Participation in another clinical study with IP and/or intervention within 30 days prior to Visit 1
13. Individuals at risk for poor protocol or medication compliance |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy and safety outcome variable of the study is defined as the composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal ischaemic stroke (time to first event).
The secondary efficacy variable is the composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal ischaemic stroke, hospitalisation for heart failure, hospitalisation for unstable angina pectoris or hospitalisation for coronary revascularisation.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 13 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 250 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |